Understanding the patient experience with CAR-T long-term follow-up (LTFU) is essential for building a sustainable model. Catalyst Healthcare Consulting, in partnership with the Emily Whitehead Foundation, surveyed nearly 100 patients and caregivers to capture their perspectives.
The findings are outlined in the whitepaper Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers, which highlights the urgent need for patient-centered LTFU processes — an increasingly critical focus as more CAR T-cell therapies receive FDA approval and reach a growing number of patients
Scientific innovation in Cell & Gene Therapy (C>) is advancing rapidly, sparking hope for patients with rare diseases, cancer, and other debilitating conditions
Join us for this dynamic conversation on Monday, June 16th, from 2:15–3:15 PM at DIA. We’d love to connect if you’ll be attending!
If you are attending the FDLI conference, we would love to chat - reach out to us on LinkedIn!
Being rare is often a blessing: a rare gem stands out from a pile of stones, a rare talent can garner prestige and success, and a rare personality can make for an influential leader or a cultural icon.